Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07332442 | Continuous Positive Airway Pressure, Arousability and Links to Mechanisms in Obstructive Sleep Apnea | PHASE3 | RECRUITING | 250 | — | — | May 1, 2026 | Jun 1, 2030 | May 6, 2026 | 1 | United States |
Mean daily average of CPAP use over 3 months
Executive function is assessed using the validated NIH Toolbox Cognition Battery's Flanker inhibitory control and attention test. In a Flanker task, participants are required to indicate the left-right orientation of a centrally presented stimulus while inhibiting attention to the potentially incongruent stimuli that surround it (i.e., the flankers, typically two on either side). Primary outcome is the overall percent of correct responses in incongruent trials.
| Arm | Type | Description |
|---|---|---|
| Eszopiclone | EXPERIMENTAL | Participants will receive eszopiclone the night of the laboratory split-night polysomnography (PSG, sleep monitoring with and without CPAP therapy). Following polysomnography, participants continue with eszopiclone and CPAP therapy |
| Placebo | PLACEBO_COMPARATOR | Participants will receive placebo the night of the laboratory split-night polysomnography (PSG, sleep monitoring with and without CPAP therapy). Following polysomnography, participants continue with placebo and CPAP therapy |
| Name | Type | Description |
|---|---|---|
| Eszopiclone | DRUG | 3mg for \< 65 and 2mg for ≥ 65 years |
| Placebo | DRUG | Matched placebo |
Inclusion Criteria: * Able to provide informed consent. * Clinically confirmed new diagnosis of OSA: 1. Polysomnography AHI ≥ 10 per hour of sleep and/or 2. Home sleep apnea testing, respiratory even index, REI ≥ 10 per hour of recording Exclusion Criteria: * Known non-OSA related conditions...